XAGE
Longevity Health Holdings Inc.
Biotechnology
Market Cap$7M
5Y Perf.-99.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
XAGE vs GDRX
Revenue, margins, valuation, and 5-year total return — side by side.
GDRX
GoodRx Holdings, Inc.
Medical - Healthcare Information Services
Market Cap$973M
5Y Perf.-93.1%
XAGE vs GDRX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | XAGE | GDRX |
|---|---|---|
| Industry | Biotechnology | Medical - Healthcare Information Services |
| Market Cap | $7M | $973M |
| Revenue (TTM) | $1M | $788M |
| Net Income (TTM) | $-6M | $29M |
| Gross Margin | 54.6% | 81.0% |
| Operating Margin | -401.0% | 12.4% |
| Forward P/E | — | 9.0x |
| Total Debt | $639K | $60M |
| Cash & Equiv. | $157K | $262M |
XAGE vs GDRX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
XAGE
GDRX
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Longevity Health Ho… (XAGE) | 100 | 0.1 | -99.9% |
| GoodRx Holdings, In… (GDRX) | 100 | 6.9 | -93.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XAGE vs GDRX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: GDRX leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Longevity Health Holdings Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
XAGE
Longevity Health Holdings Inc.
The Growth Play
XAGE is the clearest fit if your priority is growth exposure.
- Rev growth 139.4%, EPS growth 32.4%
- 139.4% revenue growth vs GDRX's 0.6%
Best for: growth exposure
GDRX
GoodRx Holdings, Inc.
The Income Pick
GDRX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 1.58
- -94.4% 10Y total return vs XAGE's -99.9%
- Lower volatility, beta 1.58, Low D/E 9.7%, current ratio 2.61x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | XAGE | 139.4% revenue growth vs GDRX's 0.6% |
| Quality / Margins | GDRX | 3.7% margin vs XAGE's -393.6% |
| Stability / Safety | GDRX | Beta 1.58 vs XAGE's 1.86 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | GDRX | -25.1% vs XAGE's -92.6% |
| Efficiency (ROA) | GDRX | 1.9% ROA vs XAGE's -173.9%, ROIC 13.0% vs -38.0% |
XAGE vs GDRX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
XAGE vs GDRX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGDRXLAGGINGXAGE
XAGELongevity Health Hold…
0leads
GDRXGoodRx Holdings, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs XAGEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
GDRX5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
GDRX7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
GDRX5/6
Risk & VolatilityBeta, volatility, and downside exposure
GDRX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
GDRX leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GDRX is the larger business by revenue, generating $788M annually — 540.6x XAGE's $1M. GDRX is the more profitable business, keeping 3.7% of every revenue dollar as net income compared to XAGE's -3.9%. On growth, XAGE holds the edge at +19.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | XAGELongevity Health … | GDRXGoodRx Holdings, … |
|---|---|---|
| RevenueTrailing 12 months | $1M | $788M |
| EBITDAEarnings before interest/tax | -$6M | $184M |
| Net IncomeAfter-tax profit | -$6M | $29M |
| Free Cash FlowCash after capex | -$4M | $132M |
| Gross MarginGross profit ÷ Revenue | +54.6% | +81.0% |
| Operating MarginEBIT ÷ Revenue | -4.0% | +12.4% |
| Net MarginNet income ÷ Revenue | -3.9% | +3.7% |
| FCF MarginFCF ÷ Revenue | -2.6% | +16.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.8% | -4.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -4.9% | -1.3% |
GDRX leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — XAGE and GDRX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | XAGELongevity Health … | GDRXGoodRx Holdings, … |
|---|---|---|
| Market CapShares × price | $7M | $973M |
| Enterprise ValueMkt cap + debt − cash | $7M | $771M |
| Trailing P/EPrice ÷ TTM EPS | -0.64x | 33.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 8.98x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 4.01x |
| Price / SalesMarket cap ÷ Revenue | 133.03x | 1.22x |
| Price / BookPrice ÷ Book value/share | — | 1.65x |
| Price / FCFMarket cap ÷ FCF | — | 5.92x |
Evenly matched — XAGE and GDRX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
GDRX leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
GDRX delivers a 4.8% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-103 for XAGE. On the Piotroski fundamental quality scale (0–9), GDRX scores 6/9 vs XAGE's 4/9, reflecting solid financial health.
| Metric | XAGELongevity Health … | GDRXGoodRx Holdings, … |
|---|---|---|
| ROE (TTM)Return on equity | -103.5% | +4.8% |
| ROA (TTM)Return on assets | -173.9% | +1.9% |
| ROICReturn on invested capital | -38.0% | +13.0% |
| ROCEReturn on capital employed | -47.5% | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | — | 0.10x |
| Net DebtTotal debt minus cash | $481,854 | -$202M |
| Cash & Equiv.Liquid assets | $157,139 | $262M |
| Total DebtShort + long-term debt | $638,993 | $60M |
| Interest CoverageEBIT ÷ Interest expense | -293.50x | 3.61x |
GDRX leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
GDRX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GDRX five years ago would be worth $817 today (with dividends reinvested), compared to $11 for XAGE. Over the past 12 months, GDRX leads with a -25.1% total return vs XAGE's -92.6%. The 3-year compound annual growth rate (CAGR) favors GDRX at -14.9% vs XAGE's -89.8% — a key indicator of consistent wealth creation.
| Metric | XAGELongevity Health … | GDRXGoodRx Holdings, … |
|---|---|---|
| YTD ReturnYear-to-date | +6.4% | +3.3% |
| 1-Year ReturnPast 12 months | -92.6% | -25.1% |
| 3-Year ReturnCumulative with dividends | -99.9% | -38.4% |
| 5-Year ReturnCumulative with dividends | -99.9% | -91.8% |
| 10-Year ReturnCumulative with dividends | -99.9% | -94.4% |
| CAGR (3Y)Annualised 3-year return | -89.8% | -14.9% |
GDRX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
GDRX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
GDRX is the less volatile stock with a 1.58 beta — it tends to amplify market swings less than XAGE's 1.86 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GDRX currently trades 48.9% from its 52-week high vs XAGE's 3.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XAGELongevity Health … | GDRXGoodRx Holdings, … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.86x | 1.58x |
| 52-Week HighHighest price in past year | $8.27 | $5.81 |
| 52-Week LowLowest price in past year | $0.23 | $1.77 |
| % of 52W HighCurrent price vs 52-week peak | +3.9% | +48.9% |
| RSI (14)Momentum oscillator 0–100 | 48.5 | 66.1 |
| Avg Volume (50D)Average daily shares traded | 1K | 2.3M |
GDRX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | XAGELongevity Health … | GDRXGoodRx Holdings, … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $3.19 |
| # AnalystsCovering analysts | — | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +21.3% |
Insufficient data to determine a leader in this category.
Key Takeaway
GDRX leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallGoodRx Holdings, Inc. (GDRX)Leads 4 of 6 categories
Loading custom metrics...
XAGE vs GDRX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is XAGE or GDRX a better buy right now?
GoodRx Holdings, Inc.
(GDRX) offers the better valuation at 33. 3x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate GoodRx Holdings, Inc. (GDRX) a "Hold" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — XAGE or GDRX?
Over the past 5 years, GoodRx Holdings, Inc.
(GDRX) delivered a total return of -91. 8%, compared to -99. 9% for Longevity Health Holdings Inc. (XAGE). Over 10 years, the gap is even starker: GDRX returned -94. 4% versus XAGE's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — XAGE or GDRX?
By beta (market sensitivity over 5 years), GoodRx Holdings, Inc.
(GDRX) is the lower-risk stock at 1. 58β versus Longevity Health Holdings Inc. 's 1. 86β — meaning XAGE is approximately 18% more volatile than GDRX relative to the S&P 500.
04Which is growing faster — XAGE or GDRX?
On earnings-per-share growth, the picture is similar: GoodRx Holdings, Inc.
grew EPS 104. 1% year-over-year, compared to 32. 4% for Longevity Health Holdings Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — XAGE or GDRX?
GoodRx Holdings, Inc.
(GDRX) is the more profitable company, earning 3. 8% net margin versus -206. 1% for Longevity Health Holdings Inc. — meaning it keeps 3. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GDRX leads at 13. 4% versus -99. 3% for XAGE. At the gross margin level — before operating expenses — XAGE leads at 87. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — XAGE or GDRX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is XAGE or GDRX better for a retirement portfolio?
For long-horizon retirement investors, GoodRx Holdings, Inc.
(GDRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Longevity Health Holdings Inc. (XAGE) carries a higher beta of 1. 86 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GDRX: -94. 4%, XAGE: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between XAGE and GDRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(XAGE: 1975.5% · GDRX: -4.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.